Insider Buying: Alphatec (NASDAQ:ATEC) Director Buys $408,600.00 in Stock

November 3, 2026 by InsiderTrades.com

Key Points

Director David Demski bought 60,000 Alphatec shares for approximately $408,600, increasing his holdings by 13.9% to 491,635 shares. The purchase was made under a pre-arranged Rule 10b5-1 trading plan.
Alphatec’s latest quarterly results fell short of expectations, with EPS of $0.09 versus $0.10 estimated and revenue of $221.17 million versus $225.16 million expected. Revenue nevertheless grew 12.6% year over year, while the company remained unprofitable.
The stock was trading near its 52-week low and below its 50-day and 200-day moving averages. Analysts generally remain positive, with a “Moderate Buy” consensus, though several firms recently reduced their price targets.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) Director David Demski purchased 60,000 shares of the company's stock in a transaction that occurred on Friday, October 30th. The stock was acquired at an average cost of $6.81 per share, for a total transaction of $408,600.00. Following the transaction, the director owned 491,635 shares in the company, valued at $3,348,034.35. This represents a 13.90% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alphatec Stock Performance

ATEC stock opened at $7.31 on Tuesday. The company has a market capitalization of $1.13 billion, a P/E ratio of -13.29 and a beta of 0.78. Alphatec Holdings, Inc. has a 52-week low of $6.81 and a 52-week high of $23.29. The business has a 50-day simple moving average of $10.10 and a two-hundred day simple moving average of $10.57.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The medical technology company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The company had revenue of $221.17 million for the quarter, compared to the consensus estimate of $225.16 million. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 13.49%. The business's revenue for the quarter was up 12.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.03 earnings per share. As a group, sell-side analysts forecast that Alphatec Holdings, Inc. will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alphatec

Institutional investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC increased its stake in Alphatec by 130.8% in the 3rd quarter. Kestra Advisory Services LLC now owns 49,616 shares of the medical technology company's stock valued at $512,000 after buying an additional 28,114 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in shares of Alphatec during the 3rd quarter worth approximately $112,000. State of Wyoming lifted its position in shares of Alphatec by 87.7% during the 3rd quarter. State of Wyoming now owns 30,666 shares of the medical technology company's stock worth $316,000 after buying an additional 14,328 shares in the last quarter. Sterling Capital Management LLC lifted its position in shares of Alphatec by 841.5% during the 3rd quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company's stock worth $42,000 after buying an additional 3,669 shares in the last quarter. Finally, Kopp Family Office LLC boosted its stake in shares of Alphatec by 0.4% in the 3rd quarter. Kopp Family Office LLC now owns 330,266 shares of the medical technology company's stock worth $3,408,000 after buying an additional 1,303 shares during the last quarter. 66.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. TD Cowen cut their target price on Alphatec from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday. Needham & Company LLC lowered their price target on Alphatec from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Friday. Wells Fargo & Company lowered their price target on Alphatec from $14.00 to $12.00 and set an "overweight" rating for the company in a research report on Friday. UBS Group raised their price objective on Alphatec from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen downgraded shares of Alphatec from a "buy" rating to a "hold" rating in a report on Sunday, October 11th. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $16.13.

Get Our Latest Research Report on Alphatec

Key Stories Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

Positive Sentiment: Director David Demski bought 60,000 ATEC shares for approximately $408,600, increasing his direct ownership by 13.9% to 491,635 shares. The purchase may be viewed as a sign of confidence in the company’s long-term prospects, although it was executed under a pre-arranged Rule 10b5-1 plan. SEC insider transaction filing
Positive Sentiment: Canaccord Genuity lowered its price target from $19 to $16 but maintained a “buy” rating, implying substantial potential upside from recent trading levels. The reduced target nevertheless reflects a more cautious valuation outlook. Canaccord Genuity price target report
Neutral Sentiment: ATEC recently traded near its 52-week low, with its shares below both the 50-day and 200-day moving averages. These technical levels indicate continued weakness but can also attract value-oriented buyers.
Negative Sentiment: BMO Capital Markets downgraded Alphatec to “Market Perform,” adding to concerns about the stock’s near-term performance. BMO Capital Markets rating report
Negative Sentiment: Wells Fargo reduced its price target, while JPMorgan issued a pessimistic forecast, signaling that several analysts see limited near-term catalysts. Wells Fargo price target report JPMorgan forecast report
Negative Sentiment: The latest quarterly results missed consensus estimates for both earnings and revenue. Revenue still grew 12.6% year over year, but the earnings miss and ongoing losses contributed to the stock falling below its 200-day moving average and reaching a new 52-week low. Alphatec earnings and moving average report Alphatec 52-week low report

About Alphatec

(Get Free Report)

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.